THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc. (NasdaqGM:RPRX) today released initial findings from evaluation of gross necropsies conducted upon completion of the in-life portion of a six-month mouse study conducted to satisfy a portion of the FDA mandated two-species trials to demonstrate the lack of carcinogenic potential for new chemical entities. In the positive and negative controlled study, Proellex showed no gross potential for tumor induction as compared to both controls. Proellex was tested at 10, 40 and 100 times the human dose in this well-recognized and characterized study. As expected the positive control, urethane, yielded easily identifiable tumors on gross necropsy. In a previously completed battery of studies, Proellex showed no genotoxic activity, an early indicator of potential for induction of cancerous tumors.
